SCHEMBL4674904

SCHEMBL4674904

O=C(O)C(O)=CC(=O)c1csc(S(=O)(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
CYP3A4 P08684 1/20 0.38
CA2 P00918 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
ALAD P13716 1/20 0.35
WDR5 P61964 1/20 0.35
POLB P06746 1/20 0.34
MAOB P27338 1/20 0.34
FLT1 P17948 2/20 0.33
FLT4 P35916 2/20 0.33
KDR P35968 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674900 1.00 AKR1C3 (0.38) AKR1C3AKR1C2AKR1C1ALDH1A1MAPK1
SCHEMBL4671823 0.88 CA2 (0.43) ALDH1A1CA2KDM4EMAPTHSD11B1
SCHEMBL4671828 0.88 CA2 (0.43) ALDH1A1CA2KDM4EMAPTHSD11B1
SCHEMBL4672596 0.87 PTGS2 (0.38) AKR1C3AKR1C2AKR1C1CA2KMT2A
SCHEMBL4672592 0.87 PTGS2 (0.38) AKR1C3AKR1C2AKR1C1CA2KMT2A
SCHEMBL4671762 0.78 ALDH1A1 (0.42) AKR1C3AKR1C2AKR1C1ALDH1A1MAPK1
SCHEMBL4671766 0.78 ALDH1A1 (0.42) AKR1C3AKR1C2AKR1C1ALDH1A1MAPK1
SCHEMBL4675056 0.78 CXCR3 (0.33) ALDH1A1MAPK1CYP3A4MEN1KMT2A
SCHEMBL4679590 0.78 CHEK2 (0.32) ALDH1A1MAPK1CYP3A4MEN1KMT2A
SCHEMBL4674498 0.76 TDP1 (0.46) AKR1C3AKR1C2AKR1C1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1C3 30/4885AKR1C2 24/4885AKR1C1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.